NCT03186443

Pregabalin Treatment and Prevention Post-herpetic Neuralgia

Prevention Effect of Pregabalin on Postherpetic Neuralgia: A Multicenter, Randomized, Double-blind, Controlled Trial

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 342 (estimated)
• Sponsor: Second Affiliated Hospital of Guangzhou Medical University · Academic / Other
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Pregabalin is effective on herpetic neuralgia, but whether can prevention post-herpetic neuralgia still need to confirm.

Detailed description

Pregabalin has been recommended as the first-line drug for post-herpetic neuralgia (PHN) therapy currently due to its efficacy and safety. However,there was no valuable report at present on the clinical efficacy of pregabalin for acute and subacute herpetic neuralgia (SHN), expect for a smaller study which included 29 outpatients who had acute zoster pain for a period of 7-1 4 days. And it is not clear whether early application of pregabalin can reduce the incidence of PHN. Therefore, this study was rational designed to evaluate the efficacy and safety of pregabalin in the treatment of herpetic neuralgia，and follow-up to the 8 months, evaluation whether impacting the accidence of PHN. It is the first time in the international that treating acute herpetic neuralgia (AHN) and SHN with pregabalin as a large sample size clinical trial. The results of this study will be great significance for guiding the clinical medication.

Conditions

• Herpetic Neuralgia

Interventions

Type	Name	Description
DRUG	Pregabalin	Pregabalin was taken 300mg,q 12h for 6 month.
DRUG	Gabapentin	Gabapentin was taken 0.4, tid for 6 month.

Timeline

• Start date: 2017-10-01
• Primary completion: 2017-10-01
• Completion: 2017-10-01
• First posted: 2017-06-14
• Last updated: 2017-06-14

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study